Analyst Douglas Tsao of H.C. Wainwright maintained a Buy rating on Argenx Se, boosting the price target to $774.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight Argenx Se’s strong market position and impressive financial performance. The company’s Vyvgart product has shown remarkable sales growth, with a significant increase in global net sales during the second quarter, surpassing market expectations. This growth is driven by the successful launch of CIDP in Germany and Japan, as well as the expanding market share in MG, particularly with the introduction of the pre-filled syringe (PFS) option.
Furthermore, Vyvgart maintains its status as the leading FcRn product in the market, outpacing competitors like UCB’s Rystiggo and JNJ’s Imaavy. The product’s unique self-administration option, along with its proven efficacy and safety profile, contributes to high patient adherence. Additionally, the ongoing expansion into new markets and the positive feedback from clinicians regarding its clinical outcomes support the confidence in Vyvgart’s continued success. These factors collectively underpin Tsao’s optimistic outlook and the raised price target for Argenx Se.
Tsao covers the Healthcare sector, focusing on stocks such as Argenx Se, Protagonist Therapeutics, and Disc Medicine. According to TipRanks, Tsao has an average return of 12.3% and a 44.83% success rate on recommended stocks.
In another report released today, Citi also maintained a Buy rating on the stock with a $845.00 price target.